Elraglusib

DB16047InvestigationalSmall molecule

Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).

Mechanism: Pharmacologically active on Glycogen synthase kinase-3 beta
Curator reviewed
Formula / weight: C₂₂H₁₃FN₂O₅ · 404.353 g/mol (avg)
Also known as: 1H-Pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5H-1,3-dioxolo(4,5-F)indol-7-yl)- · 3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-F)indol-7-yl)-pyrrole-2,5-dione
Code names: 9-ING-41

Resolves to

Compound

Structure

InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-NSMILESCN1C=C(C2=C1C=C1OCOC1=C2)C1=C(C(=O)NC1=O)C1=COC2=CC=C(F)C=C12

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elraglusib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.